Real-World Evaluation Of First-Line (1l) Pembrolizumab (Pembro) Monotherapy For Pd-L1-Positive (Tps >= 50%), Advanced Nsclc In Japan

Y. Goto, M. L. Santorelli,K. Taniguchi,T. Kamitani, M. Irisawa, K. Kanda,M. Abe,T. Burke, H. Nokihara

ANNALS OF ONCOLOGY(2021)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要